PAZINIB 400 mg is a brand name prescription oral medication containing pazopanib, which belongs to a class of drugs called tyrosine kinase inhibitor . it is an anti-cancer treatment used for adults with advanced kidney cancer and specific types of advanced soft-tissue sarcoma. It treats advanced kidney cancer and specific types of advanced soft tissues sarcoma in adults by blocking tumor blood vessel growth and slowing cancer cell multiplication.
WHAT ARE PAZINIB 400 MG TABLETS?
PAZINIB 400 mg tablets contain pazopanib, an antineoplastic agent that is classified as a protein kinase inhibitor or tyrosine kinase inhibitor (TKI) .it function as a targeted biological therapyhttps://oncomshealthcare.com/complete-guide-to-biological-therapy-in-modern-medicine/ to slow tumor growth by blocking the blood vessel formation needed by cancer cells.
key classification:
• Pharmacological class: Tyrosine Kinase inhibitor/protein kinase inhibitor
• Therapeutic category: antineoplastic/anticancer agent(Targeted therapy)
• Active ingredient: Pazopanib (400mg)
• Primary indications: advanced renal cell carcinoma and advanced soft-tissue sarcoma
• Used in targeted cancer cell therapy: it is used as a targeted cancer cell therapy by blocking specific proteins that signal cancer cells to multiply and halts the formation of the blood vessels tumors need to grow.
• Mechanism of action: it inhibit tyrosine kinase by blocking VGEF receptors, PDGF receptors and c-kit. It prevents tumors from developing the blood vessel network required to supply oxygen and nutrients effectively starving the cancer cells. It also interfere with the internal signals driving cell division and proliferation.
WHAT ARE THE USES OF PAZINIB 400 MG TABLETS?
Uses of PAZINIB 400 mg tablets are:
1. Advanced renal cell carcinoma (RCC)
PAZINIB 400 mg is a targeted cancer therapy used to treat adults with advanced renal cell carcinoma . it act as a tyrosine kinase inhibitor ,blocking proteins that tumors needed to form blood vessels and grow , thereby slowing disease progression. It works by blocking vascular endothelial growth factors receptors (VEGFR) to cut off the blood supply feeding the tumor. It works in the following ways:
• Cell proliferation control: inhibits platelet-derived growth factor receptors (PDGFR) and c-kit to stop cancer cells from multiplying .
• First-line and follow –up treatment: used as an initial medical treatment or for paents who previously received cytokine therapies.
2. Advanced soft –tissue sarcoma (STS) in appropriate patients
PAZINIB 400 mg is a targeted cancer medicine used to treat specific adults with advanced soft tissue sarcoma (STS) who received prior chemotherapyhttps://oncomshealthcare.com/living-with-prostate-cancer-treatment-diet-lifestyle-tips/comprehensive-guide-to-chemotherapy-and-cancer-care/ , though 400 mg is frequently a reduced or staring dose for management of side effects or liver impairment rather than the standard initial full dose.
3. Use according to approved indications and oncological recommendations
PAZINIB 400 mg is a targeted multi-tyrosine-kinase inhibitor . its standard full starting dose is 800 mg once daily , meaning, a 400 mg dose typically represents a first-level dose reduction for managing toxicity or an adjustment for specific drug interactions, rather than the standard initial dose. It is first-line treatment for patients who received prior cytokine therapy and also used in treatment of adults who received prior chemotherapy .
HOW PAZINIB WORK?
PAZINIB 400 mg works as a targeted cancer therapy by blocking specific proteins called tyrosine kinase inhibitor that signals cancer cells to grow, multiply and form new blood vessels. By cutting off the tumor’s blood supply and stopping growth signals, it starves the cancer and slows its spread. It works in the following ways:
• Inhibition of vascular endothelial growth factor receptors(VEGFRs)
PZANIB 400 mg is an oral multi-targeted tyrosine kinase inhibitor that blocks vascular endothelial growth factors receptors . by inhibiting these receptors inside endotheial cells, it stops the signals that trigger new blood vessel growth. This cuts off the tumors blood supply ,starving the cancer cells of oxygen and nutrients. VEGFRS works by blocking ATP binding pazopanib fits into the intracellular ATP –binding pocket of the receptor tyrosine kinase receptor.
• Effect on other growth –factor receptor pathways
PAZANIB 400 mg blocks not only vascular endotheial growth factor receptors (VEGFR) but also other vital growth factor pathways involved in tumor growth, pericyte support, and blood vessel formation. Stem cell inhibitor interfers with cell survivals and proliferation signaling tied to specific tumors.
• Reduction of tumor blood-vessels formation (angiogenesis)
PAZANIB 400 mg reduces tumor blood vessel formation by blocking key signaling proteins like VGEFR , PDGFR and c-kit , thereby starving the tumor of oxygen and nutrients . VGEFR blocks vascular endothelial growth factor receptors 1,2 and 3 which stops endothelial cells from forming new blood vessels. It restricts blood supply, slowing cancer cell proliferation and inducing cell death in specific advanced solid tumors.
• Slowing cancer –cell growth and disease progression
PAZINIB 400 mg contains pazopanib, a targeted tyrosine kinase inhibitor, that slows cancer progression and tumor growth by blocking specific enzymes that promote cell division and cutting off the blood supply tumors need to survive. PAZINIB works by blocking vascular endothelial growth factor receptors (VEGFR) to prevent tumors from creating new blood vessels. It also disrupts platelet –derived growth factor receptors (PDGFR) and c-KIT to stop abnormal cell multiplication.
CONCLUSION
PAZINIB 400 mg is a targeted tyrosine kinase inhibitor prescribed to treat advanced kidney cancer and specific soft-tissues sarcomas. Clinical evaluation concludes that while it effectively slows tumor progression by blocking the blood vessels growth, thereby requires monitoring for hypertension, liver function and gastrointestinal side effects. It manages advanced renal cell carcinoma and selective advanced soft-tissue sarcomas in adults. It alo act as an anti-angiogenic agent blocking VEGF receptors to cut off the blood supply sustaining tumor growth. It is not a cure but significantly delays disease advancement and manage tumor-related burdens.
FREQUENTLY ASKED QUESTIONS (FAQs):
QUESTION: WHAT IS PANAZIB 400 MG USED FOR?
PAZANIB 400 mg contains PAZOPANIB, a targeted anti-cancer medication known as a tyrosine kinase inhibitor. it is used in adults to treat advanced kidney cancer (renal cell carcinoma), and certain types of advanced soft-tissue sarcoma who have received prior chemotherapy .
QUESTION: HOW DOES PAZOPANIB WORK?
PAZNIB 400 mg is a targeted cancer therapy that work as a tyrosine kinase inhibitor . it blocks specific proteins that signals cancer cells to multiply and stops tumors from building the new blood vessels they need to grow and survive.
QUESTION: WHY ARE LIVER-FUNCTION TEST REQUIRED?
Liver function test (LFT) are required during PAZINIB 400 mg consumption because the medication carries a significant risk of drug-induced liver injury and hepatotoxicity. It frequently causes elevated liver enzymes and bilirubin , which can become severe or life-threatening if unmonitored.
REFRENCES:
1)https://www.1mg.com/drugs/votrient-400mg-tablet-152287?wpsrc=Google+Organic+Search
2)https://m.indiamart.com/proddetail/pazopanib-tablets-400-mg-25859926448.html
